PPT-Sofosbuvir-Velpatasvir in HCV Genotype 1, 2, 4, 5, or 6

ASTRAL1 Phase 3 Treatment Naïve amp Experienced Feld JJ et al N Engl J Med 2015 3732599607 Source Feld JJ et al N Engl J Med 2015 3732599607 SofosbuvirVelpatasvir. + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles. DL, . et al. . N . Engl. J Med. 2015;373:714-25.. Source: . Wyles. + Ribavirin to Prevent Post-Transplant HCV Recurrence . Phase 2. Curry . MP, et al. Gastroenterology. 2014;September 24. [. Epub. ahead of print] . Treatment. Naïve and Treatment . Experienced. Liver Transplantation. Matthew Luu, Yuan Fang (Pearl) Cai, Shiming Sun, . Ziyi Cheng. PHM142 Fall . 2016. Coordinator. : Dr. Jeffrey Henderson. Instructor: Dr. David Hampson. What is Hepatitis C? . Flaviviridae. virus family. VALENCE Trial. Phase . 3. Treatment. Naïve and Treatment . Experienced. Zeuzem. S, et al. . N . Engl. J Med. 2014;370:1993-2001. Source: . Zeuzem. S, et al. N . Engl. J Med. 2014;370:1993-. 2001.. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . SOLAR-1 (Cohorts A and B). Phase . 2 . Treatment Naïve and Treatment Experienced. Charlton M, al. Gastroenterology. 2015; 149:649-59.. Source: Charlton M, . et al. . Gastroenterology. 2015; 149:649-59.. Update. David Spach, MD. Professor of Medicine, Division of Infectious Diseases. University of Washington. Last Updated: . June 12. , 2013. Chronic Viral Diseases and Mortality in United States. Which one of the chronic viral diseases was responsible for the most number of deaths in the United States in 2007?. NIAID Retreatment. Phase . 2a . Treatment. . Experienced. Osinusi. A, . et al. . Ann Intern Med. 2014;161:634-8.. Source: . Osinusi. A, et al. Ann Intern Med. 2014;161:634-8.. Ledipasvir-Sofosbuvir Retreatment of SOF RBV Failure in HCV GT 1. University of Chicago. Chicago, Illinois. Challenges in the Management and Treatment of HIV/Hepatitis C Virus Coinfection. FORMATTED: 05/02/2016. Chicago, Illinois: May 9, 2016. From . AI . Aronsohn. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology . 2015;148:100-7. Treatment Naïve and Treatment Experienced Liver Transplantation Source: Curry MP, et for 12 weeks in liver transplant recipients with genotype 1-4. Agarwal K. J . Hepatol. . 2018;69:603-7. SOF/VEL: 400/100 mg 1 . tablet. QD. Liver transplant recipients. Recurrent HCV infection after transplantation. mHCV Genotype II Key to symbols used Global Trade Item Number Manufacturer Reference Number Lot Number In Vitro Diagnostic Medical Device Internal Control Amplification Reagent Pack A Amp Following Liver Transplantation. Phase 2. Charlton M, . et al. . Gastroenterology. 2015;148:108-17.. Treatment. Naïve and Treatment . Experienced. Liver Transplantation. Source: Charlton M, et al. Gastroenterology. 2015;148:108-17.. Kristen M. Marks, MD. Assistant Professor. Weill Cornell Medical College . New York, New York. Financial Relationships With Commercial Entities. Dr Marks was awarded research grants, paid to her institution, from Bristol-Myers Squibb, Gilead Sciences, .